medigraphic.com

2016, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2016; 17 (2)

Response to treatment with Heberprot-P® depending on the severity of the peripheral arterial disease

Álvarez LA

Language: Spanish
References: 20
Page: 130-137
PDF size: 180.93 Kb.


ABSTRACT

Introduction: Heberprot-P® presently represents a therapeutic alternative for this illness.
Objective: To determine the response to Heberprot-P® treatment in patients with diabetic foot ulcers, depending on the level of severity of the peripheral arterial disease.
Methods: Retrospective, descriptive and cross-sectional study of 156 patients with diabetic foot ulcers, who were admitted to the National Institute of Angiology and Vascular Surgery from June 2010 through December 2011. They were treated with Heberprot-P® during hospitalization. The studied variables were sex, age, type of diabetes and time of progression, level of severity of the peripheral arterial disease according to the ankle-brachial pressure indexes, and the percentage of granulation after eight-week treatment.
Results: The proportion of patients with normal level of disease was higher, 92.8% of whom positively responded to treatment whereas 7.2% did not. Among the patients with severe peripheral arterial disease, 33.3% showed no response to this treatment.
Conclusion: The patients with severe peripheral arterial disease or low ankle-brachial pressure index do not show favorable response to the administration of Heberprot-P®.


REFERENCES

  1. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(1):s64-67.

  2. Hiperglucemia, diabetes mellitus parte II: Guía de diagnóstico y manejo. ALAD. 2012;8(2):51-62.

  3. Llanes Barrios JA, Álvarez Duarte HT, Toledo Fernández AM, Fernández Montequín J, Torres Herrera OF, Chirino Carreño N, et al. Manual para la prevención, diagnóstico y tratamiento del pie diabético. Rev Cubana Angiol y Cir Vasc. 2009 [citado 10 Sept 2015];10(1):42-96. Disponible en: http://bvs.sld.cu/revistas/ang/vol10_1_09/ang06109.pdf

  4. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetología. 2008;51:747–55.

  5. Prompers L, Huijberts M, Apelqvist J. Optimal organization of health care in diabetic foot disease: introduction to the Eurodiale study. Int J Low Extrem Wounds. 2007;6:11-7.

  6. Hernández Rivero MG, Llanes Barrios JA, Acosta Lapera DS. Heberprot-P, una terapia eficaz en la prevención de la amputación en el pie diabético. Rev Cubana Angiol y Cir Vasc. 2009 [citado 10 Sept 2015];10:3-11. Disponible en: http://bvs.sld.cu/revistas/ang/vol10_1_09/ang02109.pdf

  7. Peripheral arterial disease in people with diabetes. Consensus statement. Diabetes Care. 2003;26:333-41.

  8. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, et al. Intralesional injections of Citoprot P® (Recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4:333-43.

  9. Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana MD, López-Mola E, et al. Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications 2009. Int Wound J. 2009;6(5):331-46.

  10. Brito-Zurita OR, Ortega-López S, López del Castillo Sánchez D, Vázquez-Téllez A R, Ornelas-Aguirre J M. Índice tobillo-brazo asociado a pie diabético. Estudio de casos y controles. Circulation. 2013;81:131-7.

  11. Tabatabaei Malazy O, Mohajeri-Tehrani MR, Pajouhi M, Shojaei Fard A, Amini MR, Larijani B. Iranian Diabetic Foot Research Network. Adv Skin Wound Care. 2010;23(10):450-4.

  12. Vidal Domínguez G. Factores de riesgo de amputación en el pie diabético. Rev Soc Peru Med Inter. 2010;23(4):145-61.

  13. Vidal Domínguez G, Mendoza-Cabrera H, Ticse-Aguirre R W. Evaluación de la concordancia entre los valores del índice tobillo-brazo y presiones segmentarias con amputación del pie diabético. Rev Soc Perú Med Inter. 2013;26(4):184-91.

  14. Aboyans V, Ho E, Denenberg J, Ho L, Natarajan L. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and non diabetic subjects. J Vasc Surg. 2008;48:1197-203.

  15. Bundó M, Urrea M, Muñoz L, Llussà J, Forés R, Torán P. Correlation between toe-brachial index and ankle-brachial index in patients with diabetes mellitus type 2. Med Clin (Barc). 2012;22(3):124-9.

  16. González Acosta S, Calaña González B, Marrero Rodríguez I, López Fernández R. Evolución clínica del tratamiento en el pie diabético con Heberprot-P o con el método convencional. Rev Cubana Angiol y Cir Vasc. 2011[citado 10 Sept 2015];12(2):132. Disponible en: http://bvs.sld.cu/revistas/ang/vol_11_2_11/ang07211.htm

  17. Rivero FE. Experiencias del Programa de atención integral a pacientes con pie diabético en el estado Zulia, Venezuela. Biotecnología Aplicada. 2009;27:101-9.

  18. Garelli G, Calvagno M, Tolstano A, Carrio M, Bullo F, Gómez R. Tratamiento de úlceras severas de pie diabético con factor de crecimiento epidérmico recombinante (Heberprot-P®). Análisis retrospectivo de los resultados. obtenidos en Argentina. Rev Arg Cir Cardiovasc. 2012;8(4):153–62.

  19. Papanas N, Maltenzos E. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Clin Interv Aging. 2008;3(2):233-40.

  20. Thanh L, Dinh TL, Veves A. The efficacy of Apligraf in the treatment of diabetic foot ulcers. Plastic Recons Surg Suppl. 2006;117:152-7.




2020     |     www.medigraphic.com